Savara (NASDAQ:SVRA) Trading Down 5.4% – What’s Next?

Savara Inc. (NASDAQ:SVRA) shares dropped 5.4% during mid-day trading on Thursday . The company traded as low as $5.37 and last traded at $5.3950. Approximately 264,368 shares changed hands during trading, a decline of 84% from the average session volume of 1,609,659 shares. The stock had previously closed at $5.70.

Savara News Roundup

Here are the key news stories impacting Savara this week:

• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $0.62 from a loss of $0.59, below the current consensus estimate of a $0.57 loss. Quarterly estimates were also reduced to losses of $0.16 for the third quarter and $0.15 for the fourth quarter.
• Negative Sentiment: The firm cut its 2027 EPS forecast to a loss of $0.37 from $0.34 and its 2028 forecast to a loss of $0.06 from $0.04, indicating continued operating losses over the next several years.
• Negative Sentiment: Longer-term estimates were also reduced: 2029 EPS was lowered to $0.09 from $0.11, while 2030 EPS was cut to $0.37 from $0.39. Although these forecasts still point to eventual profitability, the reductions weaken the near- and long-term earnings outlook.
• Neutral Sentiment: The revisions follow Savara’s recent quarterly results, in which the company reported a $0.16-per-share loss versus the $0.14 loss analysts expected. Investors may therefore remain focused on cash usage, execution and progress toward commercialization.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SVRA. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a research note on Saturday. Oppenheimer initiated coverage on shares of Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Price Performance

The company has a current ratio of 10.13, a quick ratio of 13.47 and a debt-to-equity ratio of 0.21. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -9.28 and a beta of 0.29. The stock has a 50-day moving average price of $5.65 and a two-hundred day moving average price of $5.48.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). As a group, equities research analysts forecast that Savara Inc. will post -0.62 EPS for the current year.

Hedge Funds Weigh In On Savara

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Savara in the 2nd quarter worth approximately $76,966,000. Polar Capital Holdings Plc acquired a new stake in shares of Savara during the fourth quarter worth $50,086,000. RTW Investments LP purchased a new stake in shares of Savara during the fourth quarter valued at $35,893,000. VR Adviser LLC increased its position in shares of Savara by 172.7% in the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock valued at $20,256,000 after acquiring an additional 5,626,624 shares during the period. Finally, Marshall Wace LLP purchased a new position in Savara in the 4th quarter worth $27,496,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.